The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...

CEO Bill Sibold hailed 2024 as a "transformational year" for Madrigal Pharmaceuticals, but Wall Street isn't as enthusiastic ...

A Midtown-based therapeutics company hopes to tap the growing market of anti-aging drugs with a suite of pharmaceutical ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Abbott Laboratories, Novartis, and Grifols have reached a settlement in their long-running legal battle over a patent ...

Will fund a pilot study to analyze longitudinal plasma samples covering a period of up to 10 years.

Spanish drugmaker Grifols has been awarded a $21 million grant from the Michael J Fox Foundation to support a pilot study to ...

Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms ...

U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding ...